Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials-Reference-Cited by-同舟云学术

Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Published:2020-09-16 Issue:9 Volume:3 Page:e2015943
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Hijazi Ziad¹²,Oldgren Jonas¹²,Lindbäck Johan²,Alexander John H.³,Alings Marco⁴,De Caterina Raffaele⁵,Eikelboom John W.⁶,Ezekowitz Michael D.⁷⁸,Held Claes¹²,Huber Kurt⁹,Hylek Elaine M.¹⁰,Granger Christopher B.³,Lopes Renato D.³,Vinereanu Dragos¹¹,Siegbahn Agneta²¹²,Wallentin Lars¹²

Affiliation:

1. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden

2. Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden

3. Duke Clinical Research Institute, Duke Medicine, Durham, North Carolina

4. University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

5. University Cardiology Division, University of Pisa, Pisa, Italy

6. Population Health Research Institute, Hamilton, Ontario, Canada

7. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

8. Cardiovascular Medicine, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania

9. Wilhelminenhospital, 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Medical Faculty, Sigmund Freud University, Vienna, Austria

10. Cardiovascular Medicine, Boston University School of Medicine, Boston, Massachusetts

11. University and Emergency Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania

12. Clinical Chemistry, Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2770652/hijazi_2020_oi_200596_1599661900.65387.pdf

Reference31 articles.

1. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.;Kirchhof;Eur Heart J,2016

2. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS [in Polish].;Valgimigli;Kardiol Pol,2017

3. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.;Sørensen;Lancet,2009

4. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.;Alexander;Eur Heart J,2014

5. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective—2016 update.;Angiolillo;Circ Cardiovasc Interv,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Practical Nomogram for Predicting the Bleeding Risk in Patients with a History of Myocardial Infarction Treating with Aspirin;Clinical and Applied Thrombosis/Hemostasis;2024-01

2. Seeking a fine balance between effective antithrombotic prophylaxis and safety drug profile in the elderly population: the special case of traumatic brain injury;Acta Neurochirurgica;2023-07-07

3. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper;Thrombosis and Haemostasis;2022-07-06

4. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society;EP Europace;2022-03-22

5. Growth Differentiation Factor-15 Based ABC (Age, Biomarkers, Clinical History)-AF (Atrial Fibrillation)-Bleeding Risk Score for Elderly Patients with Nonvalvular Atrial Fibrillation;Journal of Healthcare Engineering;2022-03-08